No connection

Search Results

Corporate Score 35 Neutral

Maze Therapeutics Secures $150 Million Through Equity and Warrant Offering

Apr 22, 2026 05:16 UTC
MAZE
Short term

Clinical-stage biopharmaceutical firm Maze Therapeutics has priced a registered offering to bolster its research and development pipeline. The capital injection is expected to extend the company's operational runway into 2029.

  • Gross proceeds estimated at $150 million
  • 5.54 million shares priced at $23.50
  • 850,000 pre-funded warrants available at $23.499
  • Funding targets APOL1-mediated kidney disease and phenylketonuria research
  • Operational runway extended to 2029

Maze Therapeutics, Inc. (MAZE) announced on Wednesday the pricing of an underwritten registered offering of common stock and pre-funded warrants, aiming to raise approximately $150 million in gross proceeds. The offering consists of 5.54 million shares of common stock priced at $23.50 per share. Additionally, the company is offering pre-funded warrants to purchase up to 850,000 shares at a price of $23.499 per warrant. The transaction is slated to close on or around April 23. The company intends to allocate the proceeds primarily toward the advancement of its clinical product candidates. Key focus areas include MZE829, targeting APOL1-mediated kidney disease, and MZE782, which is being developed for phenylketonuria and chronic kidney disease. Management stated that the net proceeds from this offering, when combined with existing cash and marketable securities, provide sufficient liquidity to fund operations through 2029. Prior to the announcement, MAZE shares closed Tuesday at $25.69, down 4.28%. In subsequent after-hours trading, the stock saw a slight uptick of 1.01% to $25.95.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 35 Bearish

Maze Therapeutics Prices $150 Million Common Stock Offering

Apr 22, 07:08

Score 65 Bullish

OpenAI Partners with Private Equity in $1.5 Billion 'DeployCo' Initiative

Apr 22, 06:58

Score 32 Bullish

Chewy Eyes Growth Pivot Through Veterinary Expansion and Margin Gains

Apr 22, 06:35

Score 30

Vicom Ltd. Names Chung Tying Chun as Deputy CEO to Strengthen Leadership Pipeline

Apr 22, 06:22

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile